Finance

Lists
ENGN:NASDAQ
enGene Therapeutics Inc
1,73 US$
0,00%
(0,00) 1D
9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Mkt. cap
115,94 მლნ.
Avg. vol.
726,56 ათ.
Volume
57,00
52-wk high
12,25 US$
52-wk low
1,40 US$
EPS
-2,08 US$
Beta
-0,29
Shares outstanding
67,02 მლნ.
No. of employees
82
Mkt. cap
115,94 მლნ.
Avg. vol.
726,56 ათ.
Volume
57,00
52-wk high
12,25 US$
52-wk low
1,40 US$
EPS
-2,08 US$
Beta
-0,29
Shares outstanding
67,02 მლნ.
No. of employees
82
News stories
From web sources and news partners
About enGene Therapeutics Inc
CEO-
Employees82
Founded-
Headquarters-
Sector-
Websiteengene.com
Analyst ratings
Based on 5 analysts giving stock ratings to ENGN in the past 3 months
Hold
Buy
1
Hold
3
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current 1,73 US$
4,00 US$ (+131,21%)
Average
2,50 US$ (+44,51%)
Lowest
2,00 US$ (+15,61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Hold
Maintained
2,00 US$
+15,6%
10/02/2026
David Dai
UBS
Hold
Reiterated
2,00 US$
+15,6%
09/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
2,00 US$
+15,6%
09/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
4,00 US$
+131,2%
09/09/2026
Judah Frommer
Morgan Stanley
Sell
Maintained
-
-
08/12/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
06/16/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
4,00 US$
+131,2%
05/08/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
4,00 US$
+131,2%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
21,50 US$
+1 142,8%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
21,50 US$
+1 142,8%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
21,50 US$
+1 142,8%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
28,00 US$
+1 518,5%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ოქტ. 2025
იან. 2026
აპრ. 2026
ივლ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
31,72 მლნ.
22,26 მლნ.
22,20 მლნ.
20,09 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,76 მლნ.
8,93 მლნ.
9,77 მლნ.
13,92 მლნ.
Operating expense
39,48 მლნ.
31,18 მლნ.
31,97 მლნ.
34,01 მლნ.
Total operating expenses
39,48 მლნ.
31,18 მლნ.
31,97 მლნ.
34,01 მლნ.
Operating income
-39,48 მლნ.
-31,18 მლნ.
-31,97 მლნ.
-34,01 მლნ.
Other non operating income
448,00 ათ.
-
-
-
EBT including unusual items
-38,38 მლნ.
-29,75 მლნ.
-30,23 მლნ.
-32,50 მლნ.
EBT excluding unusual items
-38,38 მლნ.
-29,26 მლნ.
-30,23 მლნ.
-32,50 მლნ.
Income tax expense
-497,00 ათ.
-
-
-
Effective tax rate
1,29%
-
-
-
Other operating expenses
-
-
-
-
Net income
-37,88 მლნ.
-29,75 მლნ.
-30,23 მლნ.
-32,50 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,73
-0,44
-0,43
-0,47
Interest and investment income
1,98 მლნ.
2,74 მლნ.
2,66 მლნ.
2,40 მლნ.
Interest expense
-750,00 ათ.
-732,00 ათ.
-745,00 ათ.
-843,00 ათ.
Net interest expenses
1,22 მლნ.
2,01 მლნ.
1,92 მლნ.
1,56 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-39,31 მლნ.
-31,00 მლნ.
-31,79 მლნ.
-33,84 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები